Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/23419
DC FieldValueLanguage
dc.contributor.authorRidova, Nevenkaen_US
dc.contributor.authorTrajkova, Sanjaen_US
dc.contributor.authorPopova-Labachevska, Marijaen_US
dc.contributor.authorStojanovska-Jakimovska, Simonaen_US
dc.contributor.authorNikolov, Filipen_US
dc.contributor.authorPanovska Stavridis, Irinaen_US
dc.date.accessioned2022-10-13T08:13:46Z-
dc.date.available2022-10-13T08:13:46Z-
dc.date.issued2022-06-15-
dc.identifier.citationRidova N, Trajkova S, Popova-Labachevska M, Stojanovska-Jakimovska S, Nikolov F, Panovska-Stavridis I. Early-Onset Colorectal Cancer in a Young Woman with Type 1 Gaucher Disease. Eur J Case Rep Intern Med. 2022 Jun 15;9(6):003412. doi: 10.12890/2022_003412.en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12188/23419-
dc.description.abstractIntroduction Gaucher disease (GD) is a rare inherited lysosomal storage disease characterized by multi-system impairment. One of its main features is the over-expressed chronic stimulation and activation of the immune system, which may play a crucial role in the development of some malignancies associated with GD. Case description We describe a young woman diagnosed with GD type 1 in early adulthood who developed early-onset colorectal cancer shortly after GD diagnosis and the initiation of enzyme replacement therapy. She underwent radical surgical resection of the colon and adjuvant chemotherapy due to metastatic disease in the liver. She failed first-line therapy with capecitabine and is currently being treated with irinotecan plus the monoclonal antibody cetuximab. Discussion Although there is no evidence of an association between GD and colorectal cancer, this presentation in a young woman without a family history or risk factors may indicate a link. During anticancer treatment, only grade 3 anaemia was documented and no other haematological toxicities were observed. Enzyme replacement therapy at the recommended dose is regularly administered at scheduled intervals. The dosage may be increased in future if necessary to alleviate profound cytopenia. Conclusion Anticancer treatment in patients with GD can be challenging due to the accompanying cytopenia. Optimal treatment of these patients with cancer requires greater understanding of the pathophysiology of GD and its impact on haematopoiesis.en_US
dc.language.isoenen_US
dc.publisherEuropean Federation of Internal Medicine (EFIM)en_US
dc.relation.ispartofEuropean Journal of Case Reports in Internal Medicineen_US
dc.subjectGaucher Diseaseen_US
dc.subjectenzyme repacement therapyen_US
dc.subjectcolorectal canceren_US
dc.titleEarly-onset colorectal cancer in a young woman with type 1 Gaucher diseaseen_US
dc.typeArticleen_US
dc.identifier.doi10.12890/2022_003412-
item.fulltextWith Fulltext-
item.grantfulltextopen-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
Appears in Collections:Faculty of Medicine: Journal Articles
Files in This Item:
File Description SizeFormat 
Early onset Colorectal Cancer in a Young woman with type 1 Gaucher Disease.pdf480.54 kBAdobe PDFView/Open
Show simple item record

Page view(s)

54
checked on Jul 24, 2024

Download(s)

3
checked on Jul 24, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.